Senores Pharmaceuticals (SPL) through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy’s Laboratories and its applicable affiliates. The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA.
The addressable opportunity of the acquired ANDAs in the USA is around $421 million MAT December 2024) as per IQVIA and around $1.13 Billion (MAT September 2024) as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL.
Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1688.75 |
Dr. Reddys Lab | 1108.55 |
Cipla | 1433.45 |
Lupin | 1982.65 |
Zydus Lifesciences | 859.55 |
View more.. |